MedTrace Logo

The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus

NCT05029115 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 716

Last updated 2023-01-23

No results posted yet for this study

Summary

This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus. We are to compare efficacy and safety between these two groups.

Conditions

Interventions

DRUG

SGLT2 inhibitor

Dapagliflozin, Empagliflozin

Sponsors & Collaborators

  • Ewha Womans University Mokdong Hospital

    lead OTHER

Principal Investigators

  • Sumi Jung · Ewha Womans University Mokdong Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029115 on ClinicalTrials.gov